SI
Sofinnova Investments Portfolio holdings
AUM
$1.47B
This Quarter Return
+1.95%
1 Year Return
+17.43%
3 Year Return
+337.79%
5 Year Return
+424.38%
10 Year Return
–
AUM
$1.65B
AUM Growth
+$1.65B
(+3.8%)
Cap. Flow
+$95.2M
Cap. Flow
% of AUM
5.78%
Top 10 Holdings %
Top 10 Hldgs %
61.91%
Holding
77
New
11
Increased
17
Reduced
15
Closed
10
Top Buys
| 1 |
JBIO
Jade Biosciences, Inc. Common Stock
JBIO
|
$85.8M |
| 2 |
Vera Therapeutics
VERA
|
$38.7M |
| 3 |
Biogen
BIIB
|
$38.3M |
| 4 |
Sarepta Therapeutics
SRPT
|
$23.2M |
| 5 |
Heron Therapeutics
HRTX
|
$22.8M |
Top Sells
| 1 |
Jazz Pharmaceuticals
JAZZ
|
$42.1M |
| 2 |
Eli Lilly
LLY
|
$33.7M |
| 3 |
Merus
MRUS
|
$27.4M |
| 4 |
RETA
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
|
$22.5M |
| 5 |
ITCI
Intra-Cellular Therapies Inc.
ITCI
|
$14M |
Sector Composition
| 1 | Healthcare | 98.84% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
Vertex Pharmaceuticals
VRTX
$102B
| $17.8M | 1.03% |
88,214
+42,514
| +93% | +$8.57M |
|
27
Regenxbio
RGNX
$498M
| $16.6M | 0.96% |
427,740
+66,005
| +18% | +$2.56M |
|
|
NCNA
28
NuCana
NCNA
$5.8M
| $15.5M | 0.89% |
5,599,999
| – | – |
|
|
AGEN
29
Agenus
AGEN
$136M
| $15.2M | 0.88% |
2,769,900
-708,301
| -20% | -$3.89M |
|
30
DexCom
DXCM
$30.9B
| $14.4M | 0.83% |
33,713
+6,713
| +25% | +$2.87M |
|
|
OBSV
31
DELISTED
ObsEva SA Ordinary Shares
OBSV
| $14.4M | 0.83% |
4,749,623
| – | – |
|
|
ITCI
32
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| $12.8M | 0.74% |
313,159
-341,842
| -52% | -$14M |
|
|
MRTX
33
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $12.7M | 0.73% |
78,538
-59,492
| -43% | -$9.61M |
|
34
Agios Pharmaceuticals
AGIO
$2.36B
| $12.1M | 0.7% |
+219,033
| New | +$12.1M |
|
|
RETA
35
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
| $11.3M | 0.65% |
79,601
-158,919
| -67% | -$22.5M |
|
36
uniQure
QURE
$954M
| $9.99M | 0.58% |
324,303
-102,819
| -24% | -$3.17M |
|
37
Amgen
AMGN
$153B
| $9.87M | 0.57% |
40,500
+1,632
| +4% | +$398K |
|
38
Cytokinetics
CYTK
$5.98B
| $9.53M | 0.55% |
481,323
+91,603
| +24% | +$1.81M |
|
39
Kura Oncology
KURA
$732M
| $9.27M | 0.53% |
444,372
+361,208
| +434% | +$7.53M |
|
40
MacroGenics
MGNX
$121M
| $6.3M | 0.36% |
234,504
+161,303
| +220% | +$4.33M |
|
|
CCXI
41
DELISTED
ChemoCentryx, Inc.
CCXI
| $6.24M | 0.36% |
465,637
+285,638
| +159% | +$3.82M |
|
|
MRNS
42
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
| $6.21M | 0.36% |
346,160
-24,191
| -7% | -$434K |
|
43
Coherus Oncology, Inc. Common Stock
CHRS
$146M
| $6.01M | 0.35% |
434,555
| – | – |
|
|
CYT
44
DELISTED
Cyteir Therapeutics, Inc. Common Stock
CYT
| $5.67M | 0.33% |
+265,000
| New | +$5.67M |
|
45
Immatics
IMTX
$662M
| $5.15M | 0.3% |
443,370
+58,271
| +15% | +$677K |
|
|
AMRN
46
Amarin Corp
AMRN
$311M
| $5.13M | 0.3% |
1,170,584
| – | – |
|
|
TCRR
47
DELISTED
TCR2 Therapeutics Inc. Common Stock
TCRR
| $4.86M | 0.28% |
296,282
-40,400
| -12% | -$663K |
|
48
Celldex Therapeutics
CLDX
$1.57B
| $4.51M | 0.26% |
+134,724
| New | +$4.51M |
|
49
Mirum Pharmaceuticals
MIRM
$3.75B
| $4.49M | 0.26% |
259,465
-216,936
| -46% | -$3.75M |
|
|
JNCE
50
DELISTED
Jounce Therapeutics, Inc. Common Stock
JNCE
| $4.25M | 0.24% |
624,756
+112,934
| +22% | +$768K |
|